Trials / Completed
CompletedNCT04165850
Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS
Open Label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Ciprofloxacin/Celecoxib Combination in Patients With ALS
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- NeuroSense Therapeutics Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability and routine disease progression measures (ALSFRS-R and Vital Capacity).
Detailed description
Patients will be prescribed a fixed dose combination of Ciprofloxacin and Celecoxib to be taken thrice daily, and will be monitored for safety and tolerability. Additionally, routine disease progression measures will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fixed dose combination Ciprofloxacin/Celecoxib | Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day |
Timeline
- Start date
- 2019-11-25
- Primary completion
- 2021-01-19
- Completion
- 2021-01-19
- First posted
- 2019-11-18
- Last updated
- 2021-03-03
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT04165850. Inclusion in this directory is not an endorsement.